A well-known example is the recently approved triplet therapy for ER+/HER2- breast cancer, which includes a CDK4/6 inhibitor, a PI3K/AKT/mTOR inhibitor, and endocrine therapy. This evidence concerns the gene ERBB2 and breast carcinoma.